Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2024 08:05 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

ISELIN, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom...
October 17, 2024 09:00 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment

Access the CEO Connect segment here ISELIN, N.J., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the...
September 16, 2024 08:05 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series

ISELIN, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom...
September 13, 2024 09:05 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series

Webcast replay of fireside chat now available ISELIN, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory...
September 04, 2024 08:35 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

Topline results from NORSE EIGHT expected in Q4 CY2024 ISELIN, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved...
September 03, 2024 08:45 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference

ISELIN, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom...
August 14, 2024 07:05 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update

Received European Union (EU) and United Kingdom (UK) Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the treatment of wet AMDNORSE EIGHT current enrollment pace supports topline readout...
August 12, 2024 09:05 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

ISELIN, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™...
August 07, 2024 08:35 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast

ISELIN, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that has achieved regulatory approval in the EU and UK for the first authorized...
July 30, 2024 09:10 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024

Company to participate in a fireside chat on Monday, August 5th at 8:00 AM ET ISELIN, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company...